Scholarlink

Purpose of the report <p>Conventional magnetic resonance imaging (MRI) has limitations in detecting abnormalities in autoimmune encephalitis (AIE). This retrospective study evaluated the utility of <sup>18</sup>F-DPA714 PET, a potential neuroinflammation biomarker, in MRI-negative AIE patients.</p> Materials and methods <p>60 MRI-negative possible AIE patients (mean age 31.68 ± 11.05&#xa0;years; 60% male) and ten age-matched healthy controls underwent <sup>18</sup>F-DPA714 PET. Only high-affinity translocator protein (TSPO) binders were included. Clinical severity scores (mRS, CASE) were collected. Abnormal PET uptake was defined voxel-wise, using a threshold of the mean SUVR + 2SDs derived from the HCs. 34 patients had follow-up PET/MRI post-immunotherapy.</p> Results <p>Among the 60 MRI-negative AIE patients, 39 (65%) exhibited abnormally elevated <sup>1</sup>⁸F-DPA714 uptake, with the highest positivity rate in the occipital lobes. Uptake patterns corresponded to specific symptoms, such as mesial temporal involvement in cognitive impairment. Quantitatively, baseline PET activity (SUVRmax, SUVRmean) was significantly correlated with baseline clinical severity (mRS, CASE). At follow-up, PET activity remained significantly correlated with mRS and CASE scores, and reductions in PET activity paralleled clinical improvement. Additionally, higher baseline PET activity was associated with greater subsequent brain volume loss.</p> Conclusion <p><sup>18</sup>F-DPA714 PET detected neuroinflammation in a substantial proportion of MRI-negative AIE patients, with quantitative uptake correlating with disease severity. Longitudinal findings suggest that post-treatment decreases in <sup>18</sup>F-DPA714 uptake may be associated with reduced subsequent brain volume loss. These results support the potential role of <sup>18</sup>F-DPA714 PET/MR as an adjunctive imaging method for disease assessment in MRI-negative AIE.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

18F-DPA714 PET in MRI-negative autoimmune encephalitis: a supportive approach to aiding neuroinflammation identification, disease severity correlation, and treatment response prediction

  • 期刊论文

  • 发表日期：

    2026年5月26日

查看全文
  • Huanyu Meng,
  • Yuanqi Qi,
  • Mengmeng Zhang,
  • Xilong Wang,
  • Ruize Zhou,
  • Jin Wang,
  • Ruifen Duan,
  • Xiaoyu Chen,
  • Lu He,
  • Hangxing Chunyu,
  • Qinming Zhou,
  • Qian Qu,
  • Wangxi Hai,
  • Yu Zhang,
  • Biao Li,
  • Min Zhang,
  • Sheng Chen

摘要

Purpose of the report

Conventional magnetic resonance imaging (MRI) has limitations in detecting abnormalities in autoimmune encephalitis (AIE). This retrospective study evaluated the utility of 18F-DPA714 PET, a potential neuroinflammation biomarker, in MRI-negative AIE patients.

Materials and methods

60 MRI-negative possible AIE patients (mean age 31.68 ± 11.05 years; 60% male) and ten age-matched healthy controls underwent 18F-DPA714 PET. Only high-affinity translocator protein (TSPO) binders were included. Clinical severity scores (mRS, CASE) were collected. Abnormal PET uptake was defined voxel-wise, using a threshold of the mean SUVR + 2SDs derived from the HCs. 34 patients had follow-up PET/MRI post-immunotherapy.

Results

Among the 60 MRI-negative AIE patients, 39 (65%) exhibited abnormally elevated 1⁸F-DPA714 uptake, with the highest positivity rate in the occipital lobes. Uptake patterns corresponded to specific symptoms, such as mesial temporal involvement in cognitive impairment. Quantitatively, baseline PET activity (SUVRmax, SUVRmean) was significantly correlated with baseline clinical severity (mRS, CASE). At follow-up, PET activity remained significantly correlated with mRS and CASE scores, and reductions in PET activity paralleled clinical improvement. Additionally, higher baseline PET activity was associated with greater subsequent brain volume loss.

Conclusion

18F-DPA714 PET detected neuroinflammation in a substantial proportion of MRI-negative AIE patients, with quantitative uptake correlating with disease severity. Longitudinal findings suggest that post-treatment decreases in 18F-DPA714 uptake may be associated with reduced subsequent brain volume loss. These results support the potential role of 18F-DPA714 PET/MR as an adjunctive imaging method for disease assessment in MRI-negative AIE.